PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).
Publication
, Conference
Harshman, LC; Puligandla, M; Haas, NB; Drake, CG; McDermott, DF; Signoretti, S; Cella, D; Gupta, RT; Wagner, LI; Shuch, BM; Lara, P; Kapoor, A ...
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS4597 / TPS4597
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Harshman, L. C., Puligandla, M., Haas, N. B., Drake, C. G., McDermott, D. F., Signoretti, S., … Allaf, M. (2018). PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). In Journal of Clinical Oncology (Vol. 36, pp. TPS4597–TPS4597). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps4597
Harshman, Lauren Christine, Maneka Puligandla, Naomi B. Haas, Charles G. Drake, David F. McDermott, Sabina Signoretti, David Cella, et al. “PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).” In Journal of Clinical Oncology, 36:TPS4597–TPS4597. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4597.
Harshman LC, Puligandla M, Haas NB, Drake CG, McDermott DF, Signoretti S, et al. PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4597–TPS4597.
Harshman, Lauren Christine, et al. “PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS4597–TPS4597. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps4597.
Harshman LC, Puligandla M, Haas NB, Drake CG, McDermott DF, Signoretti S, Cella D, Gupta RT, Wagner LI, Shuch BM, Lara P, Choueiri TK, Kapoor A, Heng DYC, Michaelson MD, Jewett MAS, Van Allen EM, George DJ, Carducci MA, Allaf M. PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS4597–TPS4597.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
TPS4597 / TPS4597
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences